Dyadic reports 2022 revenue up 21.9% to $2.93M; net loss narrows to $9.7M; COVID-19 vaccine trial dosing complete

DYADIC INTERNATIONAL INC

Revenue $2.93M (+21.9% YoY); net loss $9.7M ($0.34/share) vs $13.1M ($0.47) in 2021.
Cash $12.7M at year-end; received $1.27M from Alphazyme sale in Jan 2023; expects to fund ops into 2024.
Phase 1 trial of DYAI-100 COVID-19 booster: dosing complete in low/high dose groups, no serious adverse events; full report H2 2023.
Collaborations with Janssen, Phibro/Abic, global food ingredient company; Dapibus platform progress.
Five peer-reviewed publications on C1-cell platform; new corporate website.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DYADIC INTERNATIONAL INC reported financial results for year ended December 31, 2022.

Period: year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 29, 2023, Dyadic International, Inc. (“Dyadic”, or the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and recent Company progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference except for paragraphs two, three, four and five of the press release.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-008429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.